pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0297749 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Debasmita Dutta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, United States of America. Hauptthemen laut MEDLINE: Deoxycytidine, Gemcitabine, Pancreatic Neoplasms, Nanoparticles. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: BLRD VA, NIGMS NIH HHS, VA Merit Medical Systems.
Abstract (Originalsprache)
Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatment. The therapeutic limitations of GEM are primarily due to poor bioavailability and the development of chemoresistance resulting from the addiction of mutant-K-RAS/AKT/ERK signaling-mediated desmoplastic barriers with a hypoxic microenvironment. Several new therapeutic approaches, including nanoparticle-assisted drug delivery, are being investigated by us and others. This study used pH-responsive nanoparticles encapsulated ERK inhibitor (SCH772984) and surface functionalized with tumor-penetrating peptide, iRGD, to target PDAC tumors. We used a small molecule, SCH772984, to target ERK1 and ERK2 in PDAC and other cancer cells. This nanocarrier efficiently released ERKi in hypoxic and low-pH environments. We also found that the free-GEM, which is functionally weak when combined with nanoencapsulated ERKi, led to significant synergistic treatment outcomes in vitro and in vivo . In particular, the combination approaches significantly enhanced the GEM effect in PDAC growth inhibition and prolonged survival of the animals in a genetically engineered KPC (LSL-KrasG12D/+/LSL-Trp53R172H/+/Pdx-1-Cre) pancreatic cancer mouse model, which is not observed in a single therapy. Mechanistically, we anticipate that the GEM efficacy was increased as ERKi blocks desmoplasia by impairing the production of desmoplastic regulatory factors in PDAC cells and KPC mouse tumors. Therefore, 2 nd generation ERKi (SCH 772984)- iRGD-pH NPs are vital for the cellular response to GEM and denote a promising therapeutic target in PDAC with mutant K-RAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, United States of America.
- Cancer Research Unit, VA Medical Center, Kansas City, MO, United States of America.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States of America.
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, United States of America.
ORCID-Profile: Debasmita Dutta, Francisco J Diaz, Sushanta K Banerjee
Förderung
- BLRD VA
- NIGMS NIH HHS
- VA Merit Medical Systems
- VA Merit Funding System
- BLRD Research Career Scientist Award
- National Institute of General Medical Sciences
Zitieren
APA
Dutta, D., Ray, P., De, A., Ghosh, A., Hazra, R. S., Ghosh, P., Banerjee, S., Diaz, F. J., Upadhyay, S. P., Quadir, M., & Banerjee, S. K. (2024). pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PLOS ONE. https://doi.org/10.1371/journal.pone.0297749
Vancouver
Dutta D, Ray P, De A, Ghosh A, Hazra RS, Ghosh P, et al. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PLOS ONE. 2024. doi:10.1371/journal.pone.0297749
BibTeX
@article{Dutta2024,
author = {Dutta, Debasmita and Ray, Priyanka and De, Archana and Ghosh, Arnab and Hazra, Raj Shankar and Ghosh, Pratyusha and Banerjee, Snigdha and Diaz, Francisco J and Upadhyay, Sunil P and Quadir, Mohiuddin and Banerjee, Sushanta K},
title = {pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0297749}
}
EUVIMED